Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 5/20 | 0.47 |
| ▸ | NAMPT | P43490 | 1/20 | 0.44 |
| ▸ | RORC | P51449 | 1/20 | 0.43 |
| ▸ | IDO1 | P14902 | 1/20 | 0.42 |
| ▸ | USP30 | Q70CQ3 | 2/20 | 0.42 |
| ▸ | DPP4 | P27487 | 1/20 | 0.41 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.41 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.40 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | MAP3K14 | Q99558 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31602843 | 0.92 | GPR119 (0.43) | GPR119NAMPTRORCIDO1USP30 | |
| SCHEMBL18249558 | 0.90 | GPR119 (0.41) | GPR119NAMPTRORCIDO1USP30 | |
| SCHEMBL18249638 | 0.87 | GPR119 (0.47) | GPR119NAMPTRORCIDO1USP30 | |
| SCHEMBL18249668 | 0.87 | DPP4 (0.44) | GPR119NAMPTRORCIDO1USP30 | |
| SCHEMBL18249589 | 0.86 | GPR119 (0.47) | GPR119NAMPTRORCIDO1USP30 | |
| SCHEMBL31602711 | 0.86 | GPR119 (0.45) | GPR119NAMPTRORCIDO1USP30 | |
| SCHEMBL18249632 | 0.85 | DPP4 (0.47) | GPR119NAMPTRORCIDO1USP30 | |
| SCHEMBL18249580 | 0.85 | NR1H2 (0.43) | GPR119NAMPTRORCIDO1USP30 | |
| SCHEMBL31521322 | 0.84 | GPR119 (0.43) | GPR119NAMPTRORCIDO1USP30 | |
| SCHEMBL19908155 | 0.83 | GPR119 (0.52) | GPR119USP30DPP4PRMT5WDR77 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107646031-B | Azetidine derivatives as modulators of cortical catecholaminergic neurotransmission | 综合研究实验室瑞典股份公司 | 2020-11-17 | — | — | CN | disclosed |
| EP-3297987-B1 | NOVEL AZETIDINE DERIVATIVES USEFUL AS MODULATORS OF CORTICAL CATHECOLAMINERGIC NEUROTRANSMISSION | INTEGRATIVE RES LABORATORIES SWEDEN AB (SE) | 2019-05-15 | — | — | EP | disclosed |
| US-10287247-B2 | Azetidine derivatives useful as modulators of cortical cathecolaminergic neurotransmission | INTEGRATIVE RESEARCH LABORATORIES SWEDEN AB (SE) | 2019-05-14 | — | — | US | disclosed |
| US-20190031606-A1 | NOVEL AZETIDINE DERIVATIVES USEFUL AS MODULATORS OF CORTICAL CATHECOLAMINERGIC NEUROTRANSMISSION | INTEGRATIVE RESEARCH LABORATORIES SWEDEN AB (SE) | 2019-01-31 | — | — | US | disclosed |
| US-10087142-B2 | Azetidine derivatives useful as modulators of cortical cathecolaminergic neurotransmission | INTEGRATIVE RESEARCH LABORATORIES (SE) | 2018-10-02 | — | — | US | disclosed |
| US-20180141903-A1 | NOVEL AZETIDINE DERIVATIVES USEFUL AS MODULATORS OF CORTICAL CATHECOLAMINERGIC NEUROTRANSMISSION | INTEGRATIVE RESEARCH LABORATORIES SWEDEN AB (SE) | 2018-05-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180141903-A1 | NOVEL AZETIDINE DERIVATIVES USEFUL AS MODULATORS OF CORTICAL CATHECOLAMINERGIC NEUROTRANSMISSION | SLC18A2, SLC18A1, SLC18A3 | GPR119 118/4885NAMPT 3110/4885RORC 3165/4885 |
| US-10287247-B2 | Azetidine derivatives useful as modulators of cortical cathecolaminergic neurotransmission | SLC18A2, SLC6A2, SLC18A3 | GPR119 169/4885NAMPT 2660/4885RORC 3450/4885 |
| US-10087142-B2 | Azetidine derivatives useful as modulators of cortical cathecolaminergic neurotransmission | SLC18A2, SLC6A2, SLC18A1 | GPR119 111/4885NAMPT 3114/4885RORC 3166/4885 |
| US-20190031606-A1 | NOVEL AZETIDINE DERIVATIVES USEFUL AS MODULATORS OF CORTICAL CATHECOLAMINERGIC NEUROTRANSMISSION | SLC18A2, SLC6A2, SLC18A3 | GPR119 152/4885NAMPT 2812/4885RORC 3456/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.